mAb-话题@MedSci

#mAb#

1302篇内容 | 2841人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1912896, encodeId=3bc3191289666, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=NEJM：抗BDCA2抗体Litifilimab对系统性红斑狼疮的治疗作用（LILAC研究）, objectType=article, longId=738583, objectId=9adbe3858308, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9adbe3858308, replyNumber=0, likeNumber=124, createdTime=2022-11-14, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9adbe3858308, moduleTitle=NEJM：抗BDCA2抗体Litifilimab对系统性红斑狼疮的治疗作用（LILAC研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9adbe3858308)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912898, encodeId=9d53191289848, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=ESMO 2022：Sacituzumab Govitecan-hziy在HER2-低表达/HER2-0转移性乳腺癌中显示出有前景的疗效（TROPiCS-02研究）, objectType=article, longId=739076, objectId=83fde390764d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=83fde390764d, replyNumber=0, likeNumber=138, createdTime=2023-02-07, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=83fde390764d, moduleTitle=ESMO 2022：Sacituzumab Govitecan-hziy在HER2-低表达/HER2-0转移性乳腺癌中显示出有前景的疗效（TROPiCS-02研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=83fde390764d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912881, encodeId=3354191288109, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=NEJM：抗BDCA2抗体Litifilimab 治疗皮肤红斑狼疮有效和安全, objectType=article, longId=734182, objectId=530be341822b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=530be341822b, replyNumber=0, likeNumber=0, createdTime=2022-10-25, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=530be341822b, moduleTitle=NEJM：抗BDCA2抗体Litifilimab 治疗皮肤红斑狼疮有效和安全, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=530be341822b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912874, encodeId=50d419128e4f9, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Lancet Neurol：Eptinezumab可有效预防难治性偏头痛, objectType=article, longId=731071, objectId=5b57e31071d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b57e31071d5, replyNumber=0, likeNumber=110, createdTime=2023-01-21, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b57e31071d5, moduleTitle=Lancet Neurol：Eptinezumab可有效预防难治性偏头痛, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b57e31071d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912897, encodeId=f5a7191289eef, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=ESMO 2022：Trastuzumab Deruxtecan在转移性胃癌/GEJ癌中维持临床获益（DESTINY-Gastric02研究）, objectType=article, longId=739074, objectId=6781e3907456, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6781e3907456, replyNumber=0, likeNumber=131, createdTime=2022-10-21, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6781e3907456, moduleTitle=ESMO 2022：Trastuzumab Deruxtecan在转移性胃癌/GEJ癌中维持临床获益（DESTINY-Gastric02研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6781e3907456)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912877, encodeId=29f119128e7b1, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=J Allergy Clin Immunol Pract ：Dupilumab治疗特应性皮炎时嗜酸性粒细胞计数变化是否影响疗效？, objectType=article, longId=731282, objectId=a550e3128232, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a550e3128232, replyNumber=0, likeNumber=141, createdTime=2022-09-03, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a550e3128232, moduleTitle=J Allergy Clin Immunol Pract ：Dupilumab治疗特应性皮炎时嗜酸性粒细胞计数变化是否影响疗效？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a550e3128232)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912886, encodeId=8d1119128866d, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Front Genet | 中国首例由SMPD4基因变异致NEDMABA的病例分析, objectType=article, longId=735161, objectId=9ed7e3516172, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ed7e3516172, replyNumber=0, likeNumber=136, createdTime=2022-11-19, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ed7e3516172, moduleTitle=Front Genet | 中国首例由SMPD4基因变异致NEDMABA的病例分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ed7e3516172)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912866, encodeId=a2ba19128665f, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=君实生物宣布icatolimab和特瑞普利单抗近40项研究成果在2022年美国临床肿瘤学会（ASCO）年会上公布, objectType=article, longId=728850, objectId=e55ee2885022, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e55ee2885022, replyNumber=0, likeNumber=100, createdTime=2022-10-02, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e55ee2885022, moduleTitle=君实生物宣布icatolimab和特瑞普利单抗近40项研究成果在2022年美国临床肿瘤学会（ASCO）年会上公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e55ee2885022)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912882, encodeId=c61f1912882a9, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=J Clin Oncol：Brentuximab Vedotin联合AVD一线治疗早期不良霍奇金淋巴瘤的疗效优于标准疗法, objectType=article, longId=734317, objectId=5093e34317c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5093e34317c1, replyNumber=0, likeNumber=129, createdTime=2023-06-19, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5093e34317c1, moduleTitle=J Clin Oncol：Brentuximab Vedotin联合AVD一线治疗早期不良霍奇金淋巴瘤的疗效优于标准疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5093e34317c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912867, encodeId=31b7191286e07, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=NEJM Evid：Tremelimumab联合Durvalumab用于不可切除肝细胞癌的治疗, objectType=article, longId=729494, objectId=1842e294948c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1842e294948c, replyNumber=0, likeNumber=135, createdTime=2023-03-03, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1842e294948c, moduleTitle=NEJM Evid：Tremelimumab联合Durvalumab用于不可切除肝细胞癌的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1842e294948c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912854, encodeId=1fd71912854e0, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=双特异性抗体中CrossMab技术：过去的10年, objectType=article, longId=727173, objectId=f691e2717303, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f691e2717303, replyNumber=0, likeNumber=114, createdTime=2022-10-01, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f691e2717303, moduleTitle=双特异性抗体中CrossMab技术：过去的10年, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f691e2717303)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912871, encodeId=49a119128e1e8, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Eur Urol：Bempegaldesleukin加Nivolumab用于一线转移性尿路上皮癌效果如何？, objectType=article, longId=730487, objectId=eb89e30487a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb89e30487a4, replyNumber=0, likeNumber=115, createdTime=2023-05-04, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb89e30487a4, moduleTitle=Eur Urol：Bempegaldesleukin加Nivolumab用于一线转移性尿路上皮癌效果如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eb89e30487a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912851, encodeId=84581912851d0, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Clin Cancer Res：MEDI0680+Durvalumab vs 纳武单抗治疗晚期肾透明细胞癌, objectType=article, longId=726302, objectId=68e5e26302bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=68e5e26302bd, replyNumber=0, likeNumber=113, createdTime=2023-03-27, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=68e5e26302bd, moduleTitle=Clin Cancer Res：MEDI0680+Durvalumab vs 纳武单抗治疗晚期肾透明细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=68e5e26302bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912849, encodeId=82781912849a7, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=J Allergy Clin Immunol：研究揭示spesolimab治疗脓疱型银屑病的分子机制, objectType=article, longId=725898, objectId=b8bde25898e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8bde25898e9, replyNumber=0, likeNumber=111, createdTime=2022-07-26, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8bde25898e9, moduleTitle=J Allergy Clin Immunol：研究揭示spesolimab治疗脓疱型银屑病的分子机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8bde25898e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912865, encodeId=0f9e19128656b, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=JEADV:Guselkumab治疗银屑病1年效果研究, objectType=article, longId=728037, objectId=368ee28037a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=368ee28037a5, replyNumber=0, likeNumber=127, createdTime=2023-02-07, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=368ee28037a5, moduleTitle=JEADV:Guselkumab治疗银屑病1年效果研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=368ee28037a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912893, encodeId=3776191289380, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Expert Opin Biol Ther ：Suckinumab治疗掌趾银屑病, objectType=article, longId=736730, objectId=6c68e36730bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c68e36730bf, replyNumber=0, likeNumber=0, createdTime=2022-09-27, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c68e36730bf, moduleTitle=Expert Opin Biol Ther ：Suckinumab治疗掌趾银屑病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c68e36730bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912850, encodeId=0d6519128507b, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=NEJM Evid：Ravulizumab用于抗AchR抗体阳性重症肌无力效果持久有效（CHAMPION MG研究）, objectType=article, longId=726131, objectId=557fe26131ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=557fe26131ca, replyNumber=0, likeNumber=131, createdTime=2022-07-01, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=557fe26131ca, moduleTitle=NEJM Evid：Ravulizumab用于抗AchR抗体阳性重症肌无力效果持久有效（CHAMPION MG研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=557fe26131ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912837, encodeId=dd1c191283eb3, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Lancet子刊：评价tezepelumab对激素依赖型哮喘患者的激素节约效应，来自SOURCE 3期研究结果, objectType=article, longId=723558, objectId=c6cae2355856, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c6cae2355856, replyNumber=0, likeNumber=123, createdTime=2022-07-13, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c6cae2355856, moduleTitle=Lancet子刊：评价tezepelumab对激素依赖型哮喘患者的激素节约效应，来自SOURCE 3期研究结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c6cae2355856)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912834, encodeId=e4b21912834e6, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Tiragolumab联合阿替利珠单抗治疗广泛期小细胞肺癌的III期研究，结果失败（SKYSCRAPER-02研究）, objectType=article, longId=302277, objectId=26843022e794, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26843022e794, replyNumber=0, likeNumber=116, createdTime=2022-09-22, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26843022e794, moduleTitle=Tiragolumab联合阿替利珠单抗治疗广泛期小细胞肺癌的III期研究，结果失败（SKYSCRAPER-02研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26843022e794)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912841, encodeId=c1cf191284129, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=双特异性抗体 epcoritamab 治疗 LBCL 取得积极结果，包括经 CAR-T 细胞疗法治疗失败的患者, objectType=article, longId=724362, objectId=8304e2436281, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8304e2436281, replyNumber=0, likeNumber=126, createdTime=2022-07-19, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8304e2436281, moduleTitle=双特异性抗体 epcoritamab 治疗 LBCL 取得积极结果，包括经 CAR-T 细胞疗法治疗失败的患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8304e2436281)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

mAb

2020-05-29

snf701207 (审核中...)

前往app查看评论内容

#mAb#

NEJM：抗BDCA2抗体Litifilimab对系统性红斑狼疮的治疗作用（LILAC研究）

2022-11-14

snf701207 (审核中...)

前往app查看评论内容

#mAb#

ESMO 2022：Sacituzumab Govitecan-hziy在HER2-低表达/HER2-0转移性乳腺癌中显示出有前景的疗效（TROPiCS-02研究）

2023-02-07

snf701207 (审核中...)

前往app查看评论内容

#mAb#

NEJM：抗BDCA2抗体Litifilimab 治疗皮肤红斑狼疮有效和安全

2022-10-25

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Lancet Neurol：Eptinezumab可有效预防难治性偏头痛

2023-01-21

snf701207 (审核中...)

前往app查看评论内容

#mAb#

ESMO 2022：Trastuzumab Deruxtecan在转移性胃癌/GEJ癌中维持临床获益（DESTINY-Gastric02研究）

2022-10-21

snf701207 (审核中...)

前往app查看评论内容

#mAb#

J Allergy Clin Immunol Pract ：Dupilumab治疗特应性皮炎时嗜酸性粒细胞计数变化是否影响疗效？

2022-09-03

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Front Genet | 中国首例由SMPD4基因变异致NEDMABA的病例分析

2022-11-19

snf701207 (审核中...)

前往app查看评论内容

#mAb#

君实生物宣布icatolimab和特瑞普利单抗近40项研究成果在2022年美国临床肿瘤学会（ASCO）年会上公布

2022-10-02

snf701207 (审核中...)

前往app查看评论内容

#mAb#

J Clin Oncol：Brentuximab Vedotin联合AVD一线治疗早期不良霍奇金淋巴瘤的疗效优于标准疗法

2023-06-19

snf701207 (审核中...)

前往app查看评论内容

#mAb#

NEJM Evid：Tremelimumab联合Durvalumab用于不可切除肝细胞癌的治疗

2023-03-03

snf701207 (审核中...)

前往app查看评论内容

#mAb#

双特异性抗体中CrossMab技术：过去的10年

2022-10-01

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Eur Urol：Bempegaldesleukin加Nivolumab用于一线转移性尿路上皮癌效果如何？

2023-05-04

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Clin Cancer Res：MEDI0680+Durvalumab vs 纳武单抗治疗晚期肾透明细胞癌

2023-03-27

snf701207 (审核中...)

前往app查看评论内容

#mAb#

J Allergy Clin Immunol：研究揭示spesolimab治疗脓疱型银屑病的分子机制

2022-07-26

snf701207 (审核中...)

前往app查看评论内容

#mAb#

JEADV:Guselkumab治疗银屑病1年效果研究

2023-02-07

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Expert Opin Biol Ther ：Suckinumab治疗掌趾银屑病

2022-09-27

snf701207 (审核中...)

前往app查看评论内容

#mAb#

NEJM Evid：Ravulizumab用于抗AchR抗体阳性重症肌无力效果持久有效（CHAMPION MG研究）

2022-07-01

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Lancet子刊：评价tezepelumab对激素依赖型哮喘患者的激素节约效应，来自SOURCE 3期研究结果

2022-07-13

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Tiragolumab联合阿替利珠单抗治疗广泛期小细胞肺癌的III期研究，结果失败（SKYSCRAPER-02研究）

2022-09-22

snf701207 (审核中...)

前往app查看评论内容

#mAb#

双特异性抗体 epcoritamab 治疗 LBCL 取得积极结果，包括经 CAR-T 细胞疗法治疗失败的患者

2022-07-19

科室
- - 订阅+
  - 更多科室
工具
服务